Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S director Marianne Soegaard has filed an amended Form 3 detailing her ownership of ordinary shares and warrants. She reports direct holdings of 3,361,687 ordinary shares, plus additional ordinary shares held indirectly through Soegaard & Jansen ApS and family members. The filing also lists multiple warrant positions over Evaxion ordinary shares with exercise prices ranging from $0.0590 to $5.3800 per share and expiration dates extending to 2036-12-31.
Evaxion A/S director Wegner Lars Aage Staal has reported his equity holdings in the company in an amended Form 3. The filing shows direct ownership of 129,139 Ordinary Shares and multiple series of Warrants over additional Ordinary Shares with different exercise prices and expiration dates.
The holdings include Warrants over 46,100 Ordinary Shares at an exercise price of $0.0590 per share expiring on January 31, 2030, and Warrants over 479,604 Ordinary Shares at $0.1000 per share expiring on December 31, 2036. Other reported Warrants cover 21,396 Ordinary Shares at $5.3800 per share and 36,765 Ordinary Shares at $0.7400 per share, with various vesting schedules and expiration dates noted in the disclosure.
Evaxion A/S Chief Executive Officer Helen Tayton-Martin filed an amended Form 3 reporting her equity interests in the company. She holds warrants directly over 2,500,000 underlying ordinary shares at an exercise price of $0.1200 per share, expiring on December 31, 2031, vesting monthly over 36 months from the initial exercise date. She also reports indirect ownership of 2,286,150 ordinary shares held by her spouse, James Noble.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop vaccines, is highlighting new research at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026.
In collaboration with the Gates Foundation, Evaxion has created novel design concepts for polio vaccines, including hybrid capsid designs and de novo designed B-cell antigen approaches, aiming to combine strengths of existing inactivated and attenuated vaccines. The company will also present data from EVX‑V1, its next-generation multi-component cytomegalovirus vaccine program built from AI-discovered and AI-optimized antigens.
Evaxion A/S Chief Scientific Officer Birgitte Rono filed an amended Form 3 to update her equity holdings. The filing lists multiple warrant positions over Evaxion ordinary shares, including warrants exercisable at prices ranging from 0.07 to 5.38 with expirations extending to 2036-12-31. One warrant series relates to a private placement that closed on 2023-12-21, and certain awards vest monthly over 36 months from their initial exercise dates. The amendment also shows direct ownership of 36,765 ordinary shares, giving investors a clearer picture of her current stake.
Evaxion A/S Chief Financial Officer Thomas Frederik Schmidt has amended his initial statement of beneficial ownership to update his equity holdings. The filing shows direct ownership of 645,750 ordinary shares and warrants that are exercisable into 322,850 ordinary shares at an exercise price of $0.0590 per share.
The warrants relate to a public offering that closed on January 31, 2025 and expire on January 31, 2030. The Form 3/A records these positions as holdings rather than new purchases or sales, giving a snapshot of his current direct stake in Evaxion.
Evaxion A/S director Roberto Prego has updated his Form 3/A to detail his equity interests. As of March 18, 2026, he holds 494,410 Ordinary Shares directly and 676,620 Ordinary Shares indirectly through Prego Fidaco Investment, an entity controlled by his father.
He also holds a range of warrants on Ordinary Shares with different exercise prices and long-dated expirations, including positions exercisable at 0.7400, 0.0590, and 0.1000 per share, among others. Some warrants stem from a private placement that closed on December 21, 2023 and a public offering that closed on January 31, 2025, with vesting described as 1/12 per month over 12 months from the initial exercise date.
Evaxion A/S filed a Form 6-K to furnish a press release convening its Annual General Meeting. The meeting will be held on April 16, 2026 at 14:00 CET at the company’s offices in Hørsholm, Denmark. Shareholders can access the agenda, proposals and related materials on Evaxion’s website.
The company describes itself as a clinical-stage TechBio business using its AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases, and includes standard forward-looking statement language outlining key business and financial risks.
Evaxion A/S has called its annual general meeting for 16 April 2026 at 14:00 (CEST) in Hørsholm, Denmark and circulated the agenda and proxy materials. Shareholders will vote on approval of the audited 2025 annual report, carryforward of the year’s loss, re-election of four current directors, and election of Jens Bitsch‑Nørhave as a new board member. They will also vote on re‑appointment of EY as auditor.
The board proposes expanding its warrant authorization so it may issue warrants with a total nominal share capital of up to DKK 11,900,000 and related share capital increases without pre‑emptive rights, at market-based exercise prices. It also seeks a new authorization to issue convertible loan notes allowing conversion into shares with a total nominal capital increase of up to DKK 73,500,000, again without pre‑emptive rights, at prices aligned with the listed market price. The company’s current nominal share capital is DKK 104,252,689, corresponding to 417,010,756 shares of DKK 0.25 each, each share carrying one vote at the meeting.
Evaxion A/S filed an initial Form 3 showing its direct ownership in EVAX securities. The filing lists 129,139 Ordinary Shares held directly, plus multiple series of warrants over additional Ordinary Shares with different exercise prices and long-dated expirations.
Examples include warrants over 36,765 Ordinary Shares at an exercise price of 0.7400 expiring on 21 December 2026, and warrants over 46,100 Ordinary Shares at an exercise price of 0.0590 expiring on 31 January 2030. Several other warrant positions run through 2031 and 2036, illustrating Evaxion A/S’s combined equity and derivative exposure.